MedTrace Logo

Angiotensin Converting Enzyme Inhibition in Children With Mitral Regurgitation

NCT00113698 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2014-03-13

No results posted yet for this study

Summary

This study will evaluate the efficacy and safety of angiotensin converting enzyme inhibition (ACE-I) therapy for the treatment of mitral regurgitation (MR).

Conditions

  • Heart Defects, Congenital
  • Heart Septal Defects, Ventricular
  • Heart Failure, Congestive

Interventions

DRUG

Enalapril

Up-titration period is to reach the highest tolerated dose up to a maximum of 0.4 mg/kg/day

OTHER

Placebo

Placebo An inert preparation with similar appearance and taste to the drug

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Pediatric Heart Network

    collaborator OTHER

  • University of Utah

    lead OTHER

Principal Investigators

  • LuAnn Minich, MD · Primary Children's Hospital, Salt Lake City, UT

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2005-11-30
Completion
2006-01-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00113698 on ClinicalTrials.gov